Articles

  • 1 week ago | hcplive.com | Connor Iapoce

    Cardiac deaths have surged since the COVID-19 pandemic began in 2020, with sharper seasonal spikes and more deaths occurring at home, a new study finds.1A team of investigators from Mass General Brigham analyzed death certificate data from nearly 128,000 individuals who died in Massachusetts, finding that cardiac deaths exceeded expected levels between 2020 and 2023.

  • 1 week ago | consultantlive.com | Connor Iapoce

    Cardiac deaths have surged since the COVID-19 pandemic began in 2020, with sharper seasonal spikes and more deaths occurring at home, a new study finds.1A team of investigators from Mass General Brigham analyzed death certificate data from nearly 128,000 individuals who died in Massachusetts, finding that cardiac deaths exceeded expected levels between 2020 and 2023.

  • 1 week ago | hcplive.com | Connor Iapoce

    The US Food and Drug Administration (FDA) has approved hydrocortisone (KHINDIVI) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.1Announced by Eton Pharmaceuticals on May 28, 2025, this approval marked the first FDA-approved oral solution formulation of hydrocortisone, designed to address administration and dosing accuracy in patients who may have difficulty swallowing pills or special administration needs.

  • 1 week ago | hcplive.com | Connor Iapoce

    Birtamimab missed the primary endpoint in the Phase 3 AFFIRM-AL clinical trial for the treatment of AL amyloidosis, resulting in the discontinuation of development and the halt of the open-label extension.1Announced by Prothena Corporation on May 23, 2025, the company plans to cut operating costs and significantly shrink its workforce, with further details on the matter expected in June.

  • 1 week ago | hcplive.com | Connor Iapoce

    A systematic literature review of real-world evidence supported the use of baricitinib for the treatment of atopic dermatitis (AD) and alopecia areata (AA), backing similar efficacy and tolerability reported in pivotal clinical trials.1Across 76 publications matching the inclusion criteria, baricitinib, an oral selective Janus kinase 1/2 inhibitor, was linked to a high level of patient satisfaction, particularly for the treatment of itch in AD.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →